Find a lawyer
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod.
Despite economic and geopolitical disruption last year, biopharma M&A remained resilient and looks set for a busy 2024
Heightened interest rates have dampened enthusiasm for M&A and raised questions on how to fund deals
2024 promises to be a stronger year for M&A as economic stability returns and dealmakers normalise geopolitical uncertainty
A drop in venture capital activity and ongoing economic headwinds resulted in a sluggish year for deals, but 2024 shows signs of improvement
Activity Australian M&A deal value in 2023 exceeded 2022 levels, despite an approximate 10% decline in deal volume. Strong Australian M&A deal …
With the decrease in deal activity appearing to have bottomed out by the end of 2023, easing inflation and financing costs spark cautious optimism for …
After another challenging year, the French M&A market needs to show resilience and adaptability ahead of any rebound
Despite the potential for political shifts, a strong pipeline of deals and increased attention from private capital means 2024 could be a strong year …
2023 confirmed the robustness of Italian M&A as market operators learn to live with uncertainty
Despite weaker deal activity in 2023, the year ahead warrants cautious optimism amid improved economic forecasts and other market forces
Following a challenging year for deals in 2023, there are encouraging signs for 2024. But political tumult and execution challenges are never far away
Related topics
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod.